Liver fibrosis scores couldbe used for predicting adverse outcomes in patients with STEMI

Announcing a new article publication for Cardiovascular Innovations and Applications journal.

Liver fibrosis scores (LFSs) are novel tools for predicting cardiovascular events in patients with coronary artery disease. This study was aimed at examining the prognostic value of LFSs in patients with ST-segment elevation myocardial infarction (STEMI).

Between 2015 and 2019, 866 patients diagnosed with STEMI were consecutively enrolled. The definition of major cardiovascular events (MACEs) was all-cause death, nonfatal myocardial infarction, nonfatal ischemic stroke, and acute limb ischemia. The authors of this article evaluated the predictive values of LFSs for MACEs with receiver operating characteristic (ROC) curve and restricted cubic spline (RCS) analysis. Kaplan-Meier (K-M) analysis was conducted to explore the relationship between LFSs and MACEs.

During a median follow-up of 4 years, 155 MACEs were observed. K-M analysis of MACEs revealed significantly lower event-free survival rates in patients with intermediate or high, rather than low, NFS, FIB-4, BARD, and Forns scores. The multivariable-adjusted hazard ratios (95% CI) for MACEs in patients with high versus low risk scores were 1.343 (0.822-2.197) for NFS, 1.922 (1.085-3.405) for FIB-4, 2.395 (1.115-5.142) for BARD, and 2.271 (1.250-4.125) for Forns. The ROC curve indicated that the predictive ability for MACEs was non significantly improved by addition of the NFS (AUC = 0.7274), FIB-4 (AUC = 0.7199), BARD (AUC = 0.7235), and Forns (AUC = 0.7376) scores into the basic model (AUC = 0.7181). RCS revealed a tendency toward a nonlinear positive association of MACEs with NFS, FIB-4, and particularly Forns scores.

LFSs have potential utility for predicting adverse outcomes in patients with STEMI, thus indicating the importance of managing metabolic dysregulation.

Source:
Journal reference:

Zhu, L., et al. (2024). Liver Fibrosis Scores as Predictors of Long-term Outcomes in Patients with ST-segment Elevation Myocardial Infarction. Cardiovascular Innovations and Applications. doi.org/10.15212/cvia.2023.0095.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Two diabetes medications more beneficial in preventing major cardiovascular events